ASX-Dividend-Report-Banner

Congratulations to Sanyou Bio for achieving ISO9001 & IPMS certifications

October 18, 2023 12:00 AM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 Congratulations to Sanyou Bio for achieving ISO9001 & IPMS certifications
Image source: Kalkine Media

SHANGHAI, Oct. 17, 2023 /PRNewswire/ -- Sanyou Biopharmaceuticals Co., Ltd is pleased to announce in October 2023, we have obtained ISO 9001 and IPMS certifications. These certifications emphasize Sanyou's commitment to consistency, reliability, and accountability in our innovative biopharmaceutical drug R&D and technical services in the field of biomedical science and technology.

ISO9001:2015 is a globally recognized international quality management system standards and IPMS certification represents the highest level of accreditation for intellectual property management system in China.

Sanyou is committed to bridging the gap between drug R&D and the entire life-cycle manufacturing supply chain. We have established the 4C business model that integrate "differentiated CRO, integrated CDO, innovative CPO and characteristic CRS". Our proprietary platform and technology undergo continuous optimization, with periodic upgrades and new version of services and technologies, all aimed at becoming the most trusted partner in the hearts of our customers.

About Sanyou

Sanyou Biopharmaceuticals Co., Ltd. is a world-leading high-tech biotechnology enterprise focusing on R&D and services of innovative biological drugs. We received National-level certification as a high-tech enterprise, are recognized as a Specialized and Sophisticated enterprise by the Shanghai Municipal Government, are part of the "Zhangjiang Star" incubation program in Shanghai, have been certified as an innovative small and medium-sized enterprise,and passed the ISO9001 quality assurance certification. Sanyou is committed to bridge drug R&D and all-life-cycle manufacture supply chain, and has built the 4C business patterns that integrate "differentiated CRO, integrated CDO, innovative CPO and characteristic CRS", to accomplish the mission "to make it easy to discover innovative biological drugs anywhere".

Since its establishment 8 years ago, Sanyou has maintained rapid growth. As of september 2023, the company has a professional team of nearly 300 employees, and most of them have a Ph.D. or master degree. Sanyou's team possesses rich experience in innovative drug development and industrialization. Sanyou has established an integrated innovative biological drug R&D laboratory of twenty thousand square meters with advanced facilities in Shanghai Caohejing Hi-Tech Park.

Sanyou has built three industry-leading innovative technology platforms featured by "super-trillion, integration, and intelligence" , and has built more than 50 sub-platforms with the core innovative technologies represented by super-trillion phage display platform, and supported by platforms of material preparation, antibody discovery, molecule optimization, in vitro and in vivo efficacy, production cell line construction, upstream and downstream process development, preclinical R&D, industrialization development, etc.

Sanyou's proprietary platform and technology are in continuous optimisation,we launch from time to time upgrades and new version of services and technologies based on principles of innovation, outstanding and reliability. Our business network has expanded to all parts of the world, including China, US and Europe, and established branches in Boston, San Diego, Philadelphia, Rotterdam and London. Our company has established friendly business collaboration with more than 1000 pharmaceutical companies, drug R&D institutions and diagnostics companies worldwide.

Excellence and innovation, pursuit of dreams, striving and evolving, for the benefit of patients. Sanyou looks forward to jointly building a long-term collaborative growth ecosystem and a healthy community with our clients and partners.

You can visit us more: https://www.sanyoubio.com


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.